Anavex Life Sciences Corp (AVXL)

[Investor2014]

Sold some this morning expecting a rehash, but I see subtleties:

The most common adverse event (AE): mild dizziness
§ When pa3ents were first dosed with highest dose
§ Was transient and reversible

I take that to mean that AE being a cause for reducing dose may not be the case.

Supported also by slides 17 to 21 pointing to the differences in therapeutic concentrations and/or their effect is suspected to be genetic.

Best case, analysis is being completed and trial start dependent on thorough understanding of inclusion/exclusion criteria. Still not a proponent of the waiting for FDA etc. theory.